Design Therapeutics, Inc. $DSGN Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. reduced its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 15.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,125 shares of the company’s stock after selling 5,792 shares during the quarter. Assenagon Asset Management S.A. owned about 0.05% of Design Therapeutics worth $105,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. MPM Bioimpact LLC raised its stake in Design Therapeutics by 0.6% during the 1st quarter. MPM Bioimpact LLC now owns 562,943 shares of the company’s stock worth $2,173,000 after acquiring an additional 3,396 shares in the last quarter. Palumbo Wealth Management LLC raised its stake in Design Therapeutics by 6.5% during the 1st quarter. Palumbo Wealth Management LLC now owns 58,278 shares of the company’s stock worth $225,000 after acquiring an additional 3,582 shares in the last quarter. American Century Companies Inc. raised its stake in Design Therapeutics by 13.5% during the 1st quarter. American Century Companies Inc. now owns 44,415 shares of the company’s stock worth $171,000 after acquiring an additional 5,300 shares in the last quarter. ProShare Advisors LLC acquired a new stake in Design Therapeutics during the 4th quarter worth $71,000. Finally, Velan Capital Investment Management LP acquired a new stake in Design Therapeutics during the 1st quarter worth $54,000. 56.64% of the stock is currently owned by institutional investors and hedge funds.

Design Therapeutics Price Performance

Shares of NASDAQ:DSGN opened at $6.57 on Monday. The company’s fifty day moving average price is $5.23 and its 200 day moving average price is $4.33. Design Therapeutics, Inc. has a 12 month low of $2.60 and a 12 month high of $7.77. The firm has a market capitalization of $374.16 million, a P/E ratio of -5.87 and a beta of 1.61.

Design Therapeutics (NASDAQ:DSGN) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.02). On average, sell-side analysts anticipate that Design Therapeutics, Inc. will post -0.91 EPS for the current year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.